Toggle Navigation
Each
Pod
Each
Pod
Podcasts
Episodes
Genres
Login
Oncology Times - OncTimes Talk
RET Fusion-Targeted Drug Doubles Progression-Free Survival in NSCLC Patients
RET Fusion-Targeted Drug Doubles Progression-Free Survival in NSCLC Patients
Author
Oncology Times
Published
Fri 16 Feb 2024
Episode Link
https://traffic.libsyn.com/secure/otbroadcastsarchives/OT_POD_EP61_020624.mp3.mp3
Share to:
